Janux Therapeutics
JANX
181 hedge funds and large institutions have $1.81B invested in Janux Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 96 increasing their positions, 45 reducing their positions, and 53 closing their positions.
295% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $4.35M
113% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 45
1.5% more ownership
Funds ownership: 110.97% → 112.47% (+1.5%)
16% less funds holding
Funds holding: 216 → 181 (-35)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
47% less capital invested
Capital invested by funds: $3.43B → $1.81B (-$1.63B)
66% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 53
Top Buyers
Top Sellers
| 1 |
Holocene Advisors
New York
|
-$54.3M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$27.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$22.6M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$18.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MRP
226
Measured Risk Portfolios
San Diego,
California
| – | -$21.4K | -400 | Closed |
|
|
AWM
227
Avior Wealth Management
Omaha,
Nebraska
| – | -$5.25K | -98 | Closed |
|
|
LI
228
LRI Investments
Palm Beach Gardens,
Florida
| – | -$4.93K | -92 | Closed |
|
|
PAS
229
Point72 Asia (Singapore)
Singapore
| – | -$3.75K | -70 | Closed |
|
230
Creative Planning
Overland Park,
Kansas
| – | -$3.48K | -65 | Closed |
|
|
RS
231
R Squared
Central,
Hong Kong
| – | -$1.07K | -20 | Closed |
|
|
CA
232
CoreCap Advisors
Southfield,
Michigan
| – | -$482 | -9 | Closed |
|
|
QT
233
Quantbot Technologies
New York
| – | -$54 | -1 | Closed |
|
JANX Hedge Fund Activity: Q1 2025 in Review
181 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2025, worth a combined $1.81B — down 47% from $3.43B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of JANX and 18 opened new positions — a net loss of 35 holders — while 45 trimmed existing stakes and 96 added.
The largest buyer was Janus Henderson Group, adding an estimated $39M. The largest seller was Holocene Advisors, exiting entirely with an estimated $54.3M sold.
- 181 institutional investors held Janux Therapeutics (JANX) as of Q1 2025, down from 216 in Q4 2024.
- Funds reported $1.81B of Janux Therapeutics stock for Q1 2025, down 47% quarter-over-quarter.
- 18 funds opened new Janux Therapeutics positions in Q1 2025 and 53 closed out, a net change of -35 holders.
- The largest Janux Therapeutics buyer in Q1 2025 was Janus Henderson Group, an estimated $39M added.
- The largest Janux Therapeutics seller in Q1 2025 was Holocene Advisors, an estimated $54.3M sold.
Based on aggregated 13F filings for Q1 2025.